Delving into the Latest Updates on Cisplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CACP, CDDP, CIS-DDP

+ [23]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [9]

Active Indication

Biliary Tract NeoplasmsMalignant Pleural MesotheliomaChildhood Malignant Solid Neoplasm+ [75]

Inactive Indication

Adenocarcinoma of EsophagusAdvanced Bile Duct CarcinomaAdvanced Cervical Carcinoma+ [90]

Originator Organization

HQ Specialty Pharma Corp.

Active Organization

Amgen, Inc.

Bristol Myers Squibb Co.

Eli Lilly & Co.

+ [24]

Inactive Organization

Sierra Oncology, Inc.

Bayer AGEMD Serono Research & Development Institute, Inc.

+ [11]

License Organization

Chosa Oncology AB

Eleison Pharmaceuticals, Inc.

Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (19 Dec 1978),

Bladder CancerOvarian CancerTesticular Neoplasms

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Login to view timeline

Structure/Sequence

Molecular FormulaCl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS Registry15663-27-1

This phase I/II trial tests the safety and effectiveness of receiving external beam radiation therapy (EBRT) and brachytherapy along with chemotherapy, consisting of cisplatin and paclitaxel, and immunotherapy, consisting of bevacizumab and pembrolizumab, for the treatment of patients with stage IVB cervical cancer. EBRT is type of radiation therapy that uses a machine to aim high-energy rays at the cancer from outside of the body. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving EBRT and brachytherapy along with chemotherapy and immunotherapy may be a safe and effective way to treat patients with stage IVB cervical cancer.

Start Date31 Jan 2026

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+1]

NCT05403723

/ SuspendedPhase 1IIT

A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

Start Date31 Dec 2025

Sponsor / Collaborator

University of Maryland Baltimore

[+1]

100 Clinical Results associated with Cisplatin

Login to view more data

100 Translational Medicine associated with Cisplatin

Login to view more data

100 Patents (Medical) associated with Cisplatin

Login to view more data

123,302

Literatures (Medical) associated with Cisplatin

31 Dec 2025·Animal Cells and Systems

Parvimonas micra -polarized M2-like tumor-associated macrophages accelerate colorectal cancer development via IL-8 secretion

Article

Author: Kim, Hyung-Sik ; Yang, Ji Won ; Ahn, Ji-Su ; Seo, Yoojin ; Yu, Jeong Hyun ; Nguyen, Dang Khoa ; Park, Hee-Jeong ; Lee, Hyeon Seo ; Kim, Seong Hui ; Oh, Su-Jeong ; Kang, Min-Jung ; Lee, Yunji

Parvimonas micra (Pm), a periodontal pathogen, has been implicated in the impairment of anti-tumor responses in colorectal cancer (CRC). The tumor microenvironment in CRC involves tumor-associated macrophages (TAMs), which are pivotal in modulating tumor-associated immune responses. The polarization of TAMs towards an M2-like phenotype promotes CRC progression by suppressing the immune system. However, the mechanisms by which Pm affects the progression of CRC remain inadequately elucidated. In this study, we explored the impact of Pm infection on CRC cell characteristics, including proliferation, chemoresistance, migration, and macrophage polarization. We found that Pm-infected THP-1-derived macrophages exhibited elevated interleukin-10 levels, a well-established M2 marker. Conditioned media from Pm-treated THP-1 cells significantly enhanced CRC cell proliferation, cisplatin resistance, and migration, and interleukin-8 was identified as a key factor. Consistent with the in vitro results, an azoxymethane/dextran sodium sulfate mouse model treated with oral Pm showed accelerated CRC tumor growth. These results offer mechanistic insights into the influence of Pm infection on tumor microenvironment in CRC through M2-like macrophage polarization. The identified pathways may serve as potential targets for therapeutic interventions for CRC.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Review

Author: Marchetti, Andrea ; Mollica, Veronica ; Mottaran, Angelo ; Piazza, Pietro ; Rosellini, Matteo ; Danielli, Linda ; Ricci, Costantino ; Schiavina, Riccardo ; Tassinari, Elisa ; Massari, Francesco ; Santoni, Matteo

In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC's scenario. Furthermore, there are several ongoing research to investigate ICIs and other emerging immune agents in this setting; results are awaited. Additionally, current efforts have been made to assess the role of these agents in earlier disease settings, particularly in high-risk non-muscle-invasive bladder cancer (NMIBC). In our review, we analyzed the potential role of predictive and/or prognostic biomarkers that may improve patient selection and treatment efficacy. To conclude, we highlighted the upcoming changes that could redefine the standard of care for patients with early-stage UC.

31 Dec 2025·ANNALS OF MEDICINE

Review

Author: Liu, Dequan ; Zheng, Xu ; Wang, Shijin ; Zheng, Zunwen ; Wu, Guangzhen ; Jiang, Bowen ; Che, Xiangyu ; Xie, Deqian ; Li, Guandu

Cisplatin is a platinum-based drug that is frequently used to treat multiple tumors. The anti-tumor effect of cisplatin is closely related to the tumor immune microenvironment (TIME), which includes several immune cell types, such as the tumor-associated macrophages (TAMs), cytotoxic T-lymphocytes (CTLs), dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and natural killer (NK) cells. The interaction between these immune cells can promote tumor survival and chemoresistance, and decrease the efficacy of cisplatin monotherapy. Therefore, various combination treatment strategies have been devised to enhance patient responsiveness to cisplatin therapy. Cisplatin can augment anti-tumor immune responses in combination with immune checkpoint blockers (such as PD-1/PD-L1 or CTLA4 inhibitors), lipid metabolism disruptors (like FASN inhibitors and SCD inhibitors) and nanoparticles (NPs), resulting in better outcomes. Exploring the interaction between cisplatin and the TIME will help identify potential therapeutic targets for improving the treatment outcomes in cancer patients.

1,184

News (Medical) associated with Cisplatin

16 Jun 2025

·www.prnewswire.com

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or metastatic cervical cancer. The data was featured as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The subgroup analysis demonstrated that cadonilimab treatment significantly improved progression-free survival (PFS) and overall survival (OS) across different patient subgroups, including: levels of PD-L1 expression, prior treatment with concurrent chemoradiotherapy (CCRT), bevacizumab use, and age of the patients (≥65, <65). These results further demonstrate the clinical value and the global women's health impact of cadonilimab in advancing thetreatment standart for advanced cervical cancer. The results of the COMPASSION-16 study were previously published in The Lancet and presented at the 2024 International Gynecologic Cancer Society (IGCS) Global Meeting. The Lancet publication and the IGCS presentation disclosed that cadonilimab, in combination with platinum-based chemotherapy (with or without bevacizumab), significantly extended survival in both PD-L1-positive and PD-L1-negative patient populations (mOS HR 0.64, P=0.0011), and reduced the risk of disease progression and death (mPFS HR 0.62, P<0.0001). At the 2025 ASCO annual meeting, the study's principal investigator, Professor Xiaohua Wu from the Fudan University Shanghai Cancer Center, presented the subgroup analysis findings from the COMPASSION-16 study, with data cut-off as of April 30, 2024. Key Findings: Significant Reduction in Mortality Risk Across All Patient Subgroups, Regardless of PD-L1 Expression: In the CPS<1 group, mPFS was 12 months in the cadonilimab arm vs. 8.2 months in the control arm (HR=0.65), and mOS was not reached in the cadonilimab arm vs. 25.3 months in the control arm (HR=0.77). In the CPS≥1 group, mPFS was 14.7 months in the cadonilimab arm vs. 8.3 months in the control arm (HR=0.62), and mOS was not reached in the cadonilimab arm vs. 22.7 months in the control arm (HR=0.69). In the CPS≥10 group, mPFS was 17.1 months in the cadonilimab arm vs. 8.1 months in the control arm (HR=0.54), and mOS was not reached in the cadonimab arm vs. 29 months in the control arm (HR=0.68). Clinical Benefit in PFS and OS Regardless of Prior CCRT Treatment: In patients previously treated with CCRT, mPFS was 16.1 months in the cadonilimab arm vs. 7.9 months in the control arm (HR=0.55), and mOS was not reached in the cadonilimab arm vs. 22.8 months in the control arm (HR=0.54). Clinical Benefit in PFS and OS Regardless of Bevacizumab Use: In real-world settings, approximately 40% of patients are considered unsuitable for bevacizumab due to underlying conditions or bleeding/perforation risks. Cadonilimab demonstrated clinically meaningful improvements in both PFS and OS, whether or not bevacizumab was included in the treatment. In the bevacizumab-naive groups, mPFS was 11.7 months in the cadonilimab arm vs. 6.7 months in the control arm (HR=0.44), and mOS was 28.2 months in the cadonilimab arm vs. 15.1 months in the control arm (HR=0.5). Improvement in PFS and OS Across Age Subgroups, with Greater Efficacy in Patients ≥65 Years: In patients < 65 years, mPFS was 13.5 months in the cadonilimab arm vs. 9.5 months in the control arm (HR=0.68), and mOS was not reached in the cadonilimab arm vs. 25.3 months in the control arm (HR=0.69). In patients ≥ 65 years, mPFS was 12 months in the cadonilimab arm vs. 7.4 months in the control arm(HR=0.39), and mOS was 26.6 months in the cadonilimab arm vs. 15.1 months in the control arm (HR=0.49). Cadonilimab Combined with Platinum Agents (Cisplatin/Carboplatin) Improves PFS and OS: In the cisplatin arm, mPFS was 14.7 months in the cadonilimab arm vs. 8.1 months in the control arm (HR=0.49), and mOS was not reached in the cadonilimab arm vs. 23.9 months in the control arm (HR=0.43). In the carboplatin arm, mPFS was 12 months in the cadonilimab arm vs. 8.2 months in the control arm (HR=0.72), and mOS was 27.8 months in the cadonilimab arm vs. 22.8 months in the control arm (HR=0.82). In June 2022, cadonilimab was granted approval by the China National Medical Products Administration (NMPA) for the treatment of recurrent or metastatic cervical cancer in patients who had previously failed platinum-based chemotherapy. This indication has since been included in the national reimbursement list. In September 2024, the use of cadonilimab in first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma was approved by the NMPA. The use of cadonilimab in first-line treatment for advanced, recurrent, or metastatic cervical cancer was approved by the NMPA in May 2025. In addition, cadonilimab is currently being evaluated in nearly 30 registrational/Phase III and Phase II clinical trials across a number of high-incidence cancers. Preliminary results show that cadonilimab demonstrates clinical benefit for patient populationsin both the positive and the negative PD-L1 expression groups, marking a significant advancement over existing immunotherapies. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. ( 9926.HK, "Akeso") contains "forward-looking statements" . These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Drug ApprovalASCOPhase 2

16 Jun 2025

·pmlive.com

Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of adults with head and neck cancer. The drug has been authorised for use as a single-agent neoadjuvant treatment before surgery, then continued after surgery in combination with radiotherapy (with or without cisplatin) as an adjuvant treatment, and then as a single agent. Patients eligible for the regimen will have resectable locally advanced head and neck squamous cell carcinoma (HNSCC) and tumours expressing PD-L1 at a combined positive score of at least one, as determined by an FDA-approved test. This is the first authorisation for HNSCC in six years and the first overall perioperative approval for locally advanced HNSCC, according to the FDA. More than 72,680 new cases of head and neck cancer, which describes a number of different tumours that develop in or around the throat, larynx, nose, sinuses and mouth, are expected to be diagnosed in the US this year. Keytruda works by increasing the ability of the body’s immune system to help detect and fight tumour cells, and is already approved in the US as a monotherapy and as part of a combination treatment for certain patients with metastatic or unresectable, recurrent HNSCC. The regulator’s latest decision on the drug was supported by results from the phase 3 KEYNOTE-689 trial, in which the Keytruda perioperative regimen reduced the risk of disease recurrence, disease progression, or death by 30% compared to adjuvant standard of care (SOC) in PD-L1-positive patients. Median event-free survival was 59.7 months in the Keytruda arm, compared to 29.6 months in the SOC cohort. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratorie, said: “As the first perioperative anti-PD-1 treatment option for appropriate patients with resectable locally advanced HNSCC, this new treatment regimen has the potential to shift the treatment paradigm for patients and their families affected by this disease. “Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing SOC for treating certain patients with locally advanced HNSCC.” Marketing authorisation applications for Keytruda in this indication are currently under review by regulatory authorities worldwide, including in Europe.

Clinical ResultPhase 3Drug Approval

16 Jun 2025

·www.pharmaceutical-technology.com

FDA approves MSD’s Keytruda to treat head and neck cancer

MSD’s Keytruda is being studied in more than 1,600 trials across various cancers and treatment settings. Credit: Katherine Welles/Shutterstock. MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC). This is intended for adults whose tumours express PD-L1 with a combined positive score [CPS] ≥1 as measured by a test approved by the US regulator. It is supported by data from the pivotal Phase III KEYNOTE-689 trial, allowing the use of Keytruda monotherapy as a neoadjuvant treatment and continued as an adjuvant treatment in conjunction with radiotherapy, with or without cisplatin, followed by the therapy alone. Project Orbis, an initiative of the agency’s Oncology Center of Excellence, facilitated a concurrent review of Keytruda. Marketing authorisation applications are currently under review by health authorities in Australia, Brazil, Canada, Israel, Singapore and Switzerland. Regulatory authorities in Europe and Japan are reviewing applications for Keytruda. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence MSD Research Laboratories global clinical development oncology head and senior vice-president Dr Marjorie Green stated: “As the first perioperative anti-PD-1 treatment option for appropriate patients with resectable locally advanced head and neck squamous cell carcinoma, this new treatment regimen has the potential to shift the treatment paradigm for patients and their families affected by this disease. “Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.” Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. This humanised monoclonal antibody prevents PD-1 from interacting with its ligands, PD-L1 and PD-L2, leading to the activation of T lymphocytes, impacting both tumour and healthy cells. MSD’s Keytruda is being studied in more than 1,600 trials across various cancers and treatment settings. MSD has also secured FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus lower respiratory tract disease in neonates and infants. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

Phase 3Drug ApprovalClinical Result

100 Deals associated with Cisplatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00275	Cisplatin	L01XA01	DB00515

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Biliary Tract Neoplasms	Japan	Nippon Kayaku Co., Ltd.	22 Feb 2012
Malignant Pleural Mesothelioma	Japan	Nippon Kayaku Co., Ltd.	04 Jan 2007
Childhood Malignant Solid Neoplasm	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Lymphoma	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Bone Cancer	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Endometrial Carcinoma	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Germinoma	Japan	Nippon Kayaku Co., Ltd.	31 May 2004
Hepatocellular Carcinoma	Japan	Nippon Kayaku Co., Ltd.	29 Jan 2004
Osteosarcoma	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Small Cell Lung Cancer	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Solid tumor	China	Dezhou Bocheng Pharmaceutical Technology Co., Ltd.	01 Jan 1995
Solid tumor	China	Yunnan Phytopharmaceutical Co. Ltd.	01 Jan 1995
Solid tumor	China	Qilu Pharmaceutical Co., Ltd.	01 Jan 1995
Solid tumor	China	Kunming Guiyan Pharmaceutical Co., Ltd.	01 Jan 1995
Solid tumor	China	Dezhou Deyao Intelligent Pharmacy Co., Ltd.	01 Jan 1995
Stomach Cancer	Japan	Nippon Kayaku Co., Ltd.	03 Jun 1990
Esophageal Carcinoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Neuroblastoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Uterine Cervical Cancer	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Head and Neck Neoplasms	Japan	Nippon Kayaku Co., Ltd.	28 Aug 1986

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscle Invasive Bladder Carcinoma	Phase 3	Australia	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Brazil	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Canada	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	France	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Italy	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Netherlands	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Spain	AstraZeneca PLC	15 May 2025
Fallopian Tube High Grade Serous Adenocarcinoma	Phase 3	United States	GSK Plc	08 Mar 2024
Primary peritoneal carcinoma	Phase 3	United States	GSK Plc	08 Mar 2024
Lung Cancer	Phase 3	United States	Eleison Pharmaceuticals, Inc.	01 Feb 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03811002 (NRG-LU005, CTgov)	Phase 3	Small cell lung cancer limited stage	544	Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin (Arm I (Chemotherapy, Radiation Therapy))	tfqkmgwihw(zhyhqkkarn) = mznooflfcf bmztfxairy (sokvzujtkj, lqqybarnjh - utmnwqisgg) View more	-	12 Jun 2025
				Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin+Atezolizumab (Arm II (Chemotherapy, Radiation Therapy, Atezolizumab))	tfqkmgwihw(zhyhqkkarn) = ulzhqjiljq bmztfxairy (sokvzujtkj, fvdsdztzot - hmgknrvqql) View more
NCT02262325 (CTgov)	Phase 2	Non-small cell lung cancer stage IIIA \| Non-small cell lung cancer stage IIIB \| Recurrent Non-Small Cell Lung Cancer ... View more	21	3-dimensional conformal radiation therapy+etoposide+cisplatin	zisexufleh = rtdpmqjudy twszhiuweb (bdfljuvrjr, pxojzxyjce - bxawwnlbhr) View more	-	12 Jun 2025
NCT03944915 (DEPEND, CTgov)	Phase 2	Human Papillomavirus Infection \| Human Papillomavirus-Related Squamous Cell Carcinoma \| Locally Advanced Head and Neck Squamous Cell Carcinoma	35	Nivolumab+Carboplatin+Paclitaxel (Standard Chemotherapy)	xczpbvbrkt = avmniijphu atcvqwznnp (ojdairqglj, iwymvloinc - musmksnfcl) View more	-	11 May 2025
				Radiation+Filgrastim Injection+Paclitaxel+Hydroxyurea Pill+cisplatin+5-fluorouracil (De-escalated Chemotherapy)	xczpbvbrkt = ydqzgqensm atcvqwznnp (ojdairqglj, vfzsmaoxfj - ynzcabtgcl) View more
NCT02807181 (SIRCCA, CTgov)	Phase 2/3	Unresectable Intrahepatic Cholangiocarcinoma	89	gemcitabine+Cisplatin (Chemotherapy (Cisplatin-Gemcitabine))	bnloiapmdt(pbgseoaknj) = tfdykanlph xfgyiobvfk (satkprkekn, snryhlexis - yxojvlkyup) View more	-	09 May 2025
				Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)+gemcitabine+Cisplatin (Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine))	bnloiapmdt(pbgseoaknj) = yetoiwevkf xfgyiobvfk (satkprkekn, opryfgdoti - tmzygowkhn) View more
NCT03107182 (OPTIMA II \| OPTIMA-II, CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck \| HPV positive oropharyngeal squamous cell carcinoma \| Human Papillomavirus-Related Squamous Cell Carcinoma ... View more	72	Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA))	yecwknsohs = whqpgttjxy jiuxakalzf (moexzssmli, nfbqvxnzac - geqroqkjej) View more	-	06 May 2025
				Chemoradiotherapy+Nivolumab+Dexamethasone+Paclitaxel+hydroxyurea+cisplatin+Famotidine+Diphenhydramine+5-FU (Intermediate De-escalation Arm (IDA))	yecwknsohs = xkgwvhndma jiuxakalzf (moexzssmli, jsbwnkpabb - xaohjxumap) View more
NCT04162015 (not provided, AACR2025)	Phase 1	Malignant Pleural Mesothelioma Neoadjuvant	22	Nivolumab with platinum and pemetrexed	tcabqucxde(mhjfvscreq) = fpnxwvebtx pchnooktqg (uabnkcbecp ) View more	Positive	29 Apr 2025
NCT04602078 (AUREA \| SOGUG-AUREA, CTgov)	Phase 2	Urothelial Carcinoma of the Urinary Bladder \| Locally Advanced Urothelial Carcinoma \| Metastatic urothelial carcinoma	82	Cisplatin 70 mg/m2+Gemcitabine 1000 mg/m2+Atezolizumab 1200 mg/m2	ancrestmoc = ylzbqzfivm wlxomwmmfi (btchmqybit, biywxoceab - yrvrwqwbve) View more	-	24 Apr 2025
NCT02365766 (GU14-188 \| HCRN GU14-188, CTgov)	Phase 1/2	Urothelial Carcinoma of the Urinary Bladder \| Bladder Cancer \| Non-Muscle Invasive Bladder Neoplasms ... View more	83	Cisplatin+Pembrolizumab (Phase 1b Cohort I: Cisplatin-eligible - Pembrolizumab 200 mg)	nouzuhhmlc = phyvlrynrk tlfvaypjpq (gpfnxcysiw, nqgdruvlzr - ryvjxpnvjm)	-	18 Mar 2025
				Cisplatin+Pembrolizumab (Cohort I: Cisplatin Eligible - Pembrolizumab 200 mg)	fzkgqvhmfm = bwvudeooko yomiagxchx (kmgvmbkqjr, qomzxktaue - eaorzfxyay) View more
NCT04158141 (CTgov)	Phase 3	Malignant Pleural Mesothelioma	16	Pleurectomy+Carboplatin+Pemetrexed+Cisplatin+Pemetrexed Disodium (Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment))	cjaambqmad = abqzawctmz mfzossqjnm (kpyuebvbbb, uqazcuzawa - ycawmbxcho) View more	-	19 Feb 2025
				Intensity-Modulated Radiation Therapy+Carboplatin+Pemetrexed+Cisplatin+Pemetrexed Disodium (Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS))	cjaambqmad = mwrojgukjl mfzossqjnm (kpyuebvbbb, pzihjqvdtx - axuuntruzs) View more
NCT02662062 (ANZUP 1502 \| PCR-MIB, CTgov)	Phase 2	Non-Muscle Invasive Bladder Neoplasms	28	Radiotherapy+cisplatin+Pembrolizumab	cqkusuthls = lqasilgock aghojvqhcn (gosqvngwji, rltlwhwgur - dxnbizimzx) View more	-	27 Jan 2025